Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Non Operating Income (2016 - 2025)

Spyre Therapeutics' Non Operating Income history spans 11 years, with the latest figure at -$5.4 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 126.14% year-over-year to -$5.4 million; the TTM value through Dec 2025 reached $42.0 million, up 734.37%, while the annual FY2025 figure was $54.3 million, 8972.45% up from the prior year.
  • Non Operating Income reached -$5.4 million in Q4 2025 per SYRE's latest filing, down from $45.7 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $60.1 million in Q4 2023 to a low of -$57.8 million in Q2 2023.
  • Average Non Operating Income over 5 years is $2.7 million, with a median of $60500.0 recorded in 2021.
  • The largest YoY upside for Non Operating Income was 7367.95% in 2023 against a maximum downside of 53153.21% in 2023.
  • A 5-year view of Non Operating Income shows it stood at -$92000.0 in 2021, then soared by 975.0% to $805000.0 in 2022, then skyrocketed by 7367.95% to $60.1 million in 2023, then crashed by 65.91% to $20.5 million in 2024, then tumbled by 126.14% to -$5.4 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Non Operating Income are -$5.4 million (Q4 2025), $45.7 million (Q3 2025), and -$656000.0 (Q2 2025).